DGKA and glioblastoma: Taken together, these findings suggest that the MES phenotype may also confer resistance to immunotherapies, and suggest that the anti-MES activity of DGKα inhibition could reduce expression of immunosuppressive ligands on GBM cells; this could have broad implications for the use of DGKα inhibitors and other anti-MES agents as adjuncts in cancer immunotherapy.